Details for New Drug Application (NDA): 077571
✉ Email this page to a colleague
NDA 077571 describes REPAGLINIDE, which is a drug marketed by Actavis Totowa, Aurobindo Pharma Ltd, Chartwell Rx, Kenton, Macleods Pharms Ltd, Norvium Bioscience, Padagis Us, Sun Pharm Inds Inc, and Lupin Ltd, and is included in nine NDAs. It is available from seven suppliers. Additional details are available on the REPAGLINIDE profile page.
The generic ingredient in REPAGLINIDE is metformin hydrochloride; repaglinide. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.
The generic ingredient in REPAGLINIDE is metformin hydrochloride; repaglinide. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.
Summary for 077571
| Tradename: | REPAGLINIDE |
| Applicant: | Sun Pharm Inds Inc |
| Ingredient: | repaglinide |
| Patents: | 0 |
Pharmacology for NDA: 077571
| Mechanism of Action | Potassium Channel Antagonists |
Suppliers and Packaging for NDA: 077571
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| REPAGLINIDE | repaglinide | TABLET;ORAL | 077571 | ANDA | Sun Pharmaceutical Industries, Inc. | 57664-745 | 57664-745-13 | 500 TABLET in 1 BOTTLE (57664-745-13) |
| REPAGLINIDE | repaglinide | TABLET;ORAL | 077571 | ANDA | Sun Pharmaceutical Industries, Inc. | 57664-745 | 57664-745-18 | 1000 TABLET in 1 BOTTLE (57664-745-18) |
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Jul 11, 2013 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2MG | ||||
| Approval Date: | Jul 11, 2013 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
